Kura Oncology

Kura Oncology, Inc. is a biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of cancer. They generate revenue primarily through the development and commercialization of targeted therapies, including their lead product candidates tipifarnib, KO-539, and KO-2806, which are designed to inhibit specific cancer-causing genes. Founded in 2014, Kura has made significant strides in oncology research, including advancing multiple clinical trials and securing strategic collaborations to enhance their drug development pipeline.

Recent Posts by Kura Oncology

1-20 of 47